Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

European journal of ophthalmology

Volumn 13 Suppl 4, Issue , 2003, Pages

  Bernard, L M ^a   Althin, R ^a   Dhawan, R ^a   Grima, D T ^a   Lam, A ^a   Aballea S ^a  

^a i3 Global   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; LATANOPROST; PROSTAGLANDIN F;

ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG EFFECT; ECONOMICS; FRANCE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; RETROSPECTIVE STUDY; STATISTICAL MODEL;

ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FRANCE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MODELS, ECONOMETRIC; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES;

EID: 0642281880     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210301304s04     Document Type: Article

References (0)